Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Acute kidney injury requiring dialysis following carmustine and etoposide during autologous stem cell transplantation.

Li J, Khot A, Burbury K.

Chemotherapy. 2012;58(5):349-51. doi: 10.1159/000343661. Epub 2012 Nov 17.

PMID:
23171711
2.
3.

Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.

Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL Jr, Hahn T.

Bone Marrow Transplant. 2008 Apr;41(7):613-9. Epub 2007 Dec 10.

PMID:
18071290
4.

Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease.

Reece DE, Nevill TJ, Sayegh A, Spinelli JJ, Brockington DA, Barnett MJ, Klingemann HG, Connors JM, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Fairey RN, O'Reilly SE, Phillips GL.

Bone Marrow Transplant. 1999 Jun;23(11):1131-8.

5.

Risk factors for acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.

Yu ZP, Ding JH, Chen BA, Liu BC, Liu H, Li YF, Ding BH, Qian J.

Chin J Cancer. 2010 Nov;29(11):946-51.

6.

[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation].

Adam Z, Rehák Z, Koukalová R, Szturz P, Krejčí M, Pour L, Zahradová L, Moulis M, Kodet R, Nebeský T, Brejcha M, Adamová Z, Hájek R, Mayer J.

Vnitr Lek. 2012 Jan;58(1):62-71. Czech.

PMID:
22448704
7.

Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.

Phillips GL, Abboud CN, Bernstein SH, Friedberg JW, Ifthikharuddin JJ, Lancet JE, Liesveld JL, Spreng E, Johnson V, Chapman M, Vesole DH.

Semin Oncol. 2004 Dec;31(6 Suppl 18):59-61.

PMID:
15726525
8.

High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma.

Ventura GJ, Barlogie B, Hester JP, Yau JC, LeMaistre CF, Wallerstein RO, Spinolo JA, Dicke KA, Horwitz LH, Alexanian R.

Bone Marrow Transplant. 1990 Apr;5(4):265-8.

PMID:
1970939
9.

High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.

Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE.

Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11.

10.

Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.

Josting A, Reiser M, Wickramanayake PD, Rueffer U, Draube A, Söhngen D, Tesch H, Wolf J, Diehl V, Engert A.

Leuk Lymphoma. 2000 Mar;37(1-2):115-23.

PMID:
10721775
11.

Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?

Seyfarth B, Kuse R, Sonnen R, Glass B, Schmitz N, Dreger P.

Ann Hematol. 2001 Jul;80(7):398-405.

PMID:
11529465
12.

Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.

Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S.

Haematologica. 2007 Mar;92(3):389-96.

13.
15.

Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.

Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P, Malcovati L, Nascimbene C, Varettoni M, Volpini E, Klersy C, Bernasconi C.

Bone Marrow Transplant. 2000 Feb;25(3):309-13.

16.
17.

Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.

Martín A, Caballero MD, Pérez-Simón JA, López-Holgado N, Mateos MV, Cañizo MC, Miguel JF.

Bone Marrow Transplant. 2004 Oct;34(8):675-82.

PMID:
15334049
18.

High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience.

Cao TM, Horning S, Negrin RS, Hu WW, Johnston LJ, Taylor TL, Shizuru JA, Hoppe RT, Brown BW, Blume KG, Stockerl-Goldstein KE.

Biol Blood Marrow Transplant. 2001;7(5):294-301.

20.

Supplemental Content

Support Center